SuperGen Submits First NDA Module for Pancreatic Cancer Drug

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 2
Volume 12
Issue 2

DUBLIN, California-Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

DUBLIN, California—Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

Articles in this issue
COX-2 Inhibitors Decrease Toxicity due to Chemotherapy; May Help Arrest Tumor Progression
Some Activity for Gefitinib in Heavily Pretreated Breast Cancer
Brachytherapy Results Similar for Blacks, Whites
Dose-Dense Chemo Ups Survival in Node+ Breast Cancer
MR Spectroscopy IDs Breast Cancers, Node Involvement
ODAC Wants More Data on Expanded Casodex Indication
SuperGen Submits First NDA Module for Pancreatic Cancer Drug
Two Added to ONI’s Oncology Nursing Editorial Advisory Board
Bortezomib Active in Relapsed/Refractory Myeloma
Telomerase Potential Cancer Biomarker
Developing Targeted Therapy More Difficult Than Anticipated
Preoperative Chemoradiotherapy Downsizes 100% of Rectal Tumors in Phase I/II Trial
Fluorouracil/Leucovorin Maintains Leading Role, Results of Three-Drug Regimens Are Pending
Adjuvant Therapy for Rectal Cancer Still Needed in Node-Positive Cases
Adding Bevacizumab to IFL Combination Does Not Significantly Alter IFL Toxicity
Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content
There were fewer adverse effects and no treatment-related deaths associated with thermal ablation vs surgical resection for patients with colorectal liver metastases.

Thermal Ablation Elicits OS Similar to Resection in CRC Liver Metastases

Roman Fabbricatore
February 2nd 2025
Article

There were fewer adverse effects and no treatment-related deaths associated with thermal ablation vs surgical resection for patients with colorectal liver metastases.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.

Top 5 Takeaways for Gastrointestinal Cancer Management From 2025 ASCO GI

Russ Conroy
January 30th 2025
Article

Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

Russ Conroy
January 29th 2025
Article

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

T-DM1 Shows Promise in HER2+ Biliary Tract Cancer

T-DM1 Shows Promise in HER2+ Biliary Tract Cancer

Ariana Pelosci
January 28th 2025
Article

A phase 2 trial found T-DM1 to be a tolerable treatment option for patients with HER2-positive biliary tract adenocarcinoma.